SarcopeniaNCT00260442
Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
A study testing Resistance Training and Sedentary in people with Sarcopenia and Cardiovascular Disease, run by Texas A&M University at 1 site in United States.
Trial summary
The purpose of this study is to examine the effect of dietary cholesterol administered as whole egg or egg white (control)on muscle mass gain with resistance training in a young old population of men and women (age 50-69). It is hypothesized that dietary cholesterol will be significantly associated to muscle mass gain. Read more about this study
- Who is it for?
- Ages 50 to 69 yearsHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Cardiovascular Disease
- What is being tested?
- Resistance Training and Sedentary
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2005to Jan 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 69 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- men and women aged 50-69
- able to perform exercise testing and training
Who cannot join
- blood pressure > 160/100
- cardiac arrhythmias
- cancer
- hernia
- aortic aneurysm
- kidney disease
Show all 10Show fewer
- lung disease
- total cholesterol > 240 mg/dl or < 160 mg/dl
- current use of cholesterol lowering medications
- actively participating in >1 hour per week of resistance training
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to examine the effect of dietary cholesterol administered as whole egg or egg white (control)on muscle mass gain with resistance training in a young old population of men and women (age 50-69). It is hypothesized that dietary cholesterol will be significantly associated to muscle mass gain.
Read the detailed description
The primary objective of this proposal is to have 36 men and women (age 50-69) perform 12 weeks of resistance exercise training for the purpose of inducing skeletal muscle hypertrophy. These individuals will consume either 0, 1, or 3 whole eggs per day in a double-blind design to test the hypothesis that dietary cholesterol is essential for skeletal muscle hypertrophy. If so proven, this will confirm a very strong association between dietary cholesterol and hypertrophy observed in a previous study of 51 men and women (age 60-69). The current proposal is using a randomized double-blind, placebo controlled design to provide the most conclusive evidence that dietary cholesterol plays an essential role in skeletal muscle hypertrophy.
The secondary objective of this proposal is to test the hypothesis that increased dietary cholesterol consumption in the context of an exercise program does not alter blood cholesterol concentrations or other cardiovascular risk factors.
- Conditions
- Sarcopenia, Cardiovascular Disease
- Being tested
- Resistance Training, Sedentary
- Keywords
- sarcopenia, resistance training, strength training, skeletal muscle, elderly, cholesterol, aging, cardiovascular disease, nutrition, inflammation, lipids
- Medical subject headings
- Sarcopenia, Cardiovascular Diseases, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Resistance TrainingBehavioural
12 weeks, 3 times a week whole body resistance training
SedentaryBehavioural
Absence of physical activity
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | < 200 mg/day dietary cholesterol, resistance training, sedentary Receives: Behavioral: Resistance Training; Behavioral: Sedentary |
| Average intake | Experimental | 400 mg/day dietary cholesterol, resistance training, sedentary Receives: Behavioral: Resistance Training; Behavioral: Sedentary |
| High intake | Experimental | 800 mg/day dietary cholesterol, resistance training, sedentary Receives: Behavioral: Resistance Training; Behavioral: Sedentary |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary: Strength and muscle gain (DEXA)
Measured: after 12 weeks of resistance training
Secondary outcomes (1)
Secondary: Blood lipids, inflammatory markers, blood pressure
Measured: after 12 weeks of resistance training
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2005 (estimated)
- Study startNov 2005
- Primary completionMay 2008
- Study completionJan 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- Texas A&M University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Steven E.Riechman, PhD, MPH, Texas A&M University
- Investigators
- Steven E Riechman, PhD, MPH, Principal investigator, Texas A&M University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00260442
- Sponsor's protocol ID
- 06-0187
- Other IDs
- 481031-001-CA, 0600083
- Status last verified
- Sep 2025
- First submitted
- 29 Nov 2005
- Last updated
- 29 Sep 2025
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Egg Cholesterol Consumption, Blood Cholesterol and Skeletal Muscle Hypertrophy
- ClinicalTrials.gov ID
- NCT00260442
- Acronym / sponsor ID
- 06-0187
- Conditions
- Sarcopenia, Cardiovascular Disease
- Keywords
- sarcopenia, resistance training, strength training, skeletal muscle, elderly, cholesterol, aging, cardiovascular disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 36 participants (actual)
- Lead sponsor
- Texas A&M UniversityUniversity, hospital or other
- Study start
- Nov 2005
- Primary completion
- May 2008 (actual)
- Study completion
- Jan 2018 (actual)
- First posted
- 1 Dec 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to examine the effect of dietary cholesterol administered as whole egg or egg white (control)on muscle mass gain with resistance training in a young old population of men and women (age 50-69). It is hypothesized that dietary cholesterol will be significantly associated to muscle mass gain.
Detailed description
The primary objective of this proposal is to have 36 men and women (age 50-69) perform 12 weeks of resistance exercise training for the purpose of inducing skeletal muscle hypertrophy. These individuals will consume either 0, 1, or 3 whole eggs per day in a double-blind design to test the hypothesis that dietary cholesterol is essential for skeletal muscle hypertrophy. If so proven, this will confirm a very strong association between dietary cholesterol and hypertrophy observed in a previous study of 51 men and women (age 60-69). The current proposal is using a randomized double-blind, placebo controlled design to provide the most conclusive evidence that dietary cholesterol plays an essential role in skeletal muscle hypertrophy.
The secondary objective of this proposal is to test the hypothesis that increased dietary cholesterol consumption in the context of an exercise program does not alter blood cholesterol concentrations or other cardiovascular risk factors.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Behavioral: Resistance Training, Behavioral: Sedentary< 200 mg/day dietary cholesterol, resistance training, sedentary |
| Average intake | Experimental | Behavioral: Resistance Training, Behavioral: Sedentary400 mg/day dietary cholesterol, resistance training, sedentary |
| High intake | Experimental | Behavioral: Resistance Training, Behavioral: Sedentary800 mg/day dietary cholesterol, resistance training, sedentary |
Who may qualify
- Ages
- 50 to 69 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- men and women aged 50-69
- able to perform exercise testing and training
Key exclusion criteria (10 listed)
- blood pressure > 160/100
- cardiac arrhythmias
- cancer
- hernia
- aortic aneurysm
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Resistance Training12 weeks, 3 times a week whole body resistance training | Behavioural | Average intake, High intake, Placebo |
| SedentaryAbsence of physical activity | Behavioural | Average intake, High intake, Placebo |
Primary outcome
Primary: Strength and muscle gain (DEXA)
Time frame: after 12 weeks of resistance training
1 secondary outcome
Secondary: Blood lipids, inflammatory markers, blood pressure
Time frame: after 12 weeks of resistance training
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2025.
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Steven E Riechman, PhD, MPH principal investigator
Texas A&M University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Resistance Training and Sedentary in people with Sarcopenia and Cardiovascular Disease, run by Texas A&M University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary: Strength and muscle gain (DEXA) (time frame: after 12 weeks of resistance training). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025.